AI assistant
Sending…
Teva Pharmaceutical Industries Ltd. — Director's Dealing 2023
Aug 7, 2023
7082_dirs_2023-08-07_c813e856-20e2-4ff8-828e-3385881f98f4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK: 0000818686
Period of Report: 2023-08-04
Reporting Person: BARER SOL J (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-08-04 | Ordinary Shares | M | 28162 | — | Acquired | 371516 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-08-04 | Restricted Share Units | $ | M | 28162 | Disposed | Ordinary Shares (28162) | Direct |
Footnotes
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources
and Compensation Committee, the cash value of one ordinary share.
F3: Restricted share units were granted on August 4, 2022 and vested on August 4, 2023.